Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Spriggs

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|December 31, 2002
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group studyRussell J Schilder, Mark F Brady, David Spriggs, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyDiane R Mould, Gini F Fleming, Kathleen M Darcy, et al.
The Oncologist|October 27, 2005
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysisDeborah K Armstrong, David Spriggs, Jeremey Levin, et al.
The Journal of Rheumatology|November 3, 2012
Vasculitis of the female genital tract: not always a localized conditionStephen C West, L Jonathan Zwi, David Spriggs, et al.
Oncoimmunology|May 8, 2015
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>Mythili Koneru, Terence J Purdon, David Spriggs, et al.
Scientific Reports|September 7, 2017
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironmentOladapo O Yeku, Terence J Purdon, Mythili Koneru, et al.
The New Zealand Medical Journal|May 27, 2003
Stroke rehabilitation services in New ZealandJohn Gommans, Alan Barber, Harry McNaughton, et al.
Gynecologic Oncology|December 17, 2003
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experienceDon S Dizon, Jakob Dupont, Sibyl Anderson, et al.
The New Zealand Medical Journal|April 27, 2004
Changes in stroke care at Auckland Hospital between 1996 and 2001Alan Barber, Alison Charleston, Neil Anderson, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|December 31, 2002
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group studyRussell J Schilder, Mark F Brady, David Spriggs, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyDiane R Mould, Gini F Fleming, Kathleen M Darcy, et al.
The Oncologist|October 27, 2005
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysisDeborah K Armstrong, David Spriggs, Jeremey Levin, et al.
The Journal of Rheumatology|November 3, 2012
Vasculitis of the female genital tract: not always a localized conditionStephen C West, L Jonathan Zwi, David Spriggs, et al.
Oncoimmunology|May 8, 2015
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>Mythili Koneru, Terence J Purdon, David Spriggs, et al.
Scientific Reports|September 7, 2017
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironmentOladapo O Yeku, Terence J Purdon, Mythili Koneru, et al.
The New Zealand Medical Journal|May 27, 2003
Stroke rehabilitation services in New ZealandJohn Gommans, Alan Barber, Harry McNaughton, et al.
Gynecologic Oncology|December 17, 2003
Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experienceDon S Dizon, Jakob Dupont, Sibyl Anderson, et al.
The New Zealand Medical Journal|April 27, 2004
Changes in stroke care at Auckland Hospital between 1996 and 2001Alan Barber, Alison Charleston, Neil Anderson, et al.
Gynecologic Oncology|August 23, 2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman, Qin Zhou, Angela G Arnold, et al.
Pageof 5